8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ 9-THC at Human CB 1 and CB 2 Receptors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Compounds present in Cannabis sativa such as phytocannabinoids and terpenoids may act in concert to elicit therapeutic effects. Cannabinoids such as Δ 9-tetrahydrocannabinol (Δ 9-THC) directly activate cannabinoid receptor 1 (CB 1) and cannabinoid receptor 2 (CB 2); however, it is not known if terpenoids present in Cannabis also affect cannabinoid receptor signaling. Therefore, we examined six common terpenoids alone, and in combination with cannabinoid receptor agonists, on CB 1 and CB 2 signaling in vitro.

          Materials and Methods: Potassium channel activity in AtT20 FlpIn cells transfected with human CB 1 or CB 2 receptors was measured in real time using FLIPR ® membrane potential dye in a FlexStation 3 plate reader. Terpenoids were tested individually and in combination for periods up to 30 min. Endogenous somatostatin receptors served as a control for direct effects of drugs on potassium channels.

          Results: α-Pinene, β-pinene, β-caryophyllene, linalool, limonene, and β-myrcene (up to 30–100 μM) did not change membrane potential in AtT20 cells expressing CB 1 or CB 2, or affect the response to a maximally effective concentration of the synthetic cannabinoid CP55,940. The presence of individual or a combination of terpenoids did not affect the hyperpolarization produced by Δ 9-THC (10 μM): (CB 1: control, 59%±7%; with terpenoids (10 μM each) 55%±4%; CB 2: Δ 9-THC 16%±5%, with terpenoids (10 μM each) 17%±4%). To investigate possible effect on desensitization of CB 1 responses, all six terpenoids were added together with Δ 9-THC and signaling measured continuously over 30 min. Terpenoids did not affect desensitization, after 30 min the control hyperpolarization recovered by 63%±6% in the presence of the terpenoids recovery was 61%±5%.

          Discussion: None of the six of the most common terpenoids in Cannabis directly activated CB 1 or CB 2, or modulated the signaling of the phytocannabinoid agonist Δ 9-THC. These results suggest that if a phytocannabinoid–terpenoid entourage effect exists, it is not at the CB 1 or CB 2 receptor level. It remains possible that terpenoids activate CB 1 and CB 2 signaling pathways that do not involve potassium channels; however, it seems more likely that they may act at different molecular target(s) in the neuronal circuits important for the behavioral effect of Cannabis.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

          Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL(-1) . They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus). Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant. http://dx.doi.org/10.1111/bph.2011.163.issue-7. © 2011 The Author. British Journal of Pharmacology © 2011 The British Pharmacological Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.

            Cannabidiol has been reported to act as an antagonist at cannabinoid CB1 receptors. We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through negative allosteric modulation of CB1 receptors.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Phytocannabinoids: a unified critical inventory.

              Covering up to January 2016Cannabis sativa L. is a prolific, but not exclusive, producer of a diverse group of isoprenylated resorcinyl polyketides collectively known as phytocannabinoids. The modular nature of the pathways that merge into the phytocannabinoid chemotype translates in differences in the nature of the resorcinyl side-chain and the degree of oligomerization of the isoprenyl residue, making the definition of phytocannabinoid elusive from a structural standpoint. A biogenetic definition is therefore proposed, splitting the phytocannabinoid chemotype into an alkyl- and a β-aralklyl version, and discussing the relationships between phytocannabinoids from different sources (higher plants, liverworts, fungi). The startling diversity of cannabis phytocannabinoids might be, at least in part, the result of non-enzymatic transformations induced by heat, light, and atmospheric oxygen on a limited set of major constituents (CBG, CBD, Δ(9)-THC and CBC and their corresponding acidic versions), whose degradation is detailed to emphasize this possibility. The diversity of metabotropic (cannabinoid receptors), ionotropic (thermos-TRPs), and transcription factors (PPARs) targeted by phytocannabinoids is discussed. The integrated inventory of these compounds and their biological macromolecular end-points highlights the opportunities that phytocannabinoids offer to access desirable drug-like space beyond the one associated to the narcotic target CB1.
                Bookmark

                Author and article information

                Journal
                Cannabis Cannabinoid Res
                Cannabis Cannabinoid Res
                can
                Cannabis and Cannabinoid Research
                Mary Ann Liebert, Inc., publishers (140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA )
                2378-8763
                23 September 2019
                2019
                23 September 2019
                : 4
                : 3
                : 165-176
                Affiliations
                [ 1 ]Department of Biomedical Sciences, Macquarie University, Sydney, New South Wales, Australia.
                [ 2 ]The Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia.
                [ 3 ]Discipline of Pharmacology, The University of Sydney, Sydney, New South Wales, Australia.
                [ 4 ]School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.
                Author notes
                [*] [ * ]Address correspondence to: Marina Santiago, PhD, Department of Biomedical Sciences, Macquarie University, Sydney 2109, New South Wales, Australia, marina.junqueirasantiago@ 123456mq.edu.au
                Article
                10.1089/can.2019.0016
                10.1089/can.2019.0016
                6757242
                31559333
                db497ee7-125b-4706-b777-4aeb30e309b0
                © Marina Santiago et al. 2019; Published by Mary Ann Liebert, Inc.

                This Open Access article is distributed under the terms of the Creative Commons License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Page count
                Figures: 9, References: 31, Pages: 12
                Categories
                Original Research

                phytocannabinoid,cannabinoid receptor,terpenoid,entourage effect,thc,signaling

                Comments

                Comment on this article